Latest Conference Articles

October 2nd 2016, 10:08pm

NCCN Hematologic Malignancies Congress

The preferred primary therapy for patients with multiple myeloma is induction therapy with a triplet regimen followed by autologous stem cell transplantation, consolidation, and maintenance.

October 2nd 2016, 8:39pm

NCCN Hematologic Malignancies Congress

There has been some debate over what should be the standard frontline treatment for patients with chronic lymphocytic leukemia: ibrutinib or chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab.

October 2nd 2016, 3:36am

NCCN Hematologic Malignancies Congress

Thomas LeBlanc, MD, assistant professor of medicine, Duke Cancer Institute, discusses why it is important to include patients in the decision-making process for the treatment of hematologic malignancies.

October 2nd 2016, 2:39am

NCCN Hematologic Malignancies Congress

​Steven Coutre, MD, professor of medicine (hematology) at Stanford University Medical Center, discusses considerations when selecting between oral therapies like ibrutinib and chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia (CLL).

October 1st 2016, 10:30pm

NCCN Hematologic Malignancies Congress

Jessica K. Altman, MD, discussed the potential of agents poised to transform the landscape of acute myeloid leukemia.

October 1st 2016, 9:42pm

NCCN Hematologic Malignancies Congress

Ruben Mesa, MD, discussed the latest NCCN treatment guidelines for myelofibrosis and emerging treatments in the field.

October 1st 2016, 9:23pm

NCCN Hematologic Malignancies Congress

As generic imatinib enters the market, new questions focus on a renewed role for the agent in conjunction with second-generation TKIs.

October 1st 2016, 5:06am

NCCN Hematologic Malignancies Congress

​Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses the impact of the approval of generic imatinib in chronic myelogenous leukemia (CML).

October 1st 2016, 3:47am

NCCN Hematologic Malignancies Congress

Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN). Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN).

September 14th 2016, 5:41pm

International Liver Cancer Association Annual Conference

Anthony B. El-Khoueiry, MD, associate professor of Clinical Medicine, USC Norris Comprehensive Cancer Center, discusses the rationale for evaluating nivolumab in advanced hepatocellular carcinoma (HCC).

September 14th 2016, 5:36pm

International Liver Cancer Association Annual Conference

Ju Dong Yang, MD, MSc, discusses patients with nonalcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) who present without cirrhosis at the time of diagnosis of liver cancer.

September 12th 2016, 4:10am

International Liver Cancer Association Annual Conference

A new generation of drugs has proved highly effective against the hepatitis C virus but there is conflicting evidence about whether the therapies promote cancer recurrence in infected patients with hepatocellular carcinoma who already have responded to curative treatment.

September 12th 2016, 1:48am

International Liver Cancer Association Annual Conference

Ghassan K. Abou-Alfa, MD, discusses research into the use of the immunotherapeutic vaccinia virus Pexa-Vec as a frontline treatment for advanced hepatocellular carcinoma.

September 12th 2016, 12:48am

International Liver Cancer Association Annual Conference

Two competing methods of delivering locoregional therapy to patients with hepatocellular carcinoma both have advantages and may be most successful in subgroups of individuals with intermediate-stage disease.

September 11th 2016, 11:37pm

International Liver Cancer Association Annual Conference

Richard Kinh Gian Do, MD, PhD, radiologist, Memorial Sloan Kettering Cancer Center, discusses the assessment of tumor response in liver cancer.

September 11th 2016, 11:31pm

International Liver Cancer Association Annual Conference

Francis Yao, MD, professor of Clinical Medicine and Surgery, medical director of the Liver Transplant Program at UCSF Medical Center, discusses the Milan criteria in liver cancer.

September 11th 2016, 5:20am

International Liver Cancer Association Annual Conference

About one quarter of patients with nonalcoholic steatohepatitis-associated hepatocellular carcinoma present without cirrhosis at diagnosis, suggesting a crucial subset of patients for future research with implications for HCC screening and surveillance.

September 11th 2016, 5:01am

International Liver Cancer Association Annual Conference

Nivolumab continues to post durable responses in patients with advanced hepatocellular carcinoma regardless of whether they had hepatitis B or C or whether they had received prior treatment with sorafenib.

September 11th 2016, 12:15am

International Liver Cancer Association Annual Conference

After 9 years of failed trials for once-promising drugs, regorafenib (Stivarga) has emerged as the clear choice for second-line therapy in advanced hepatocellular carcinoma after demonstrating survival improvements for patients whose disease has progressed after systemic treatment.

September 10th 2016, 9:30pm

International Liver Cancer Association Annual Conference

Richard S. Finn, MD, an associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the challenges with determing a biomarker for patients with hepatocellular carcinoma (HCC) in an interview during the 10th Annual Conference of the International Liver Cancer Association (ILCA) in Vancouver, Canada. Finn is the current ILCA president.